A Randomised, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, Target Engagement and Immunogenicity of a Single Subcutaneous Dose of GSK3858279 Administered to Healthy Caucasian, Chinese and Japanese Participants
Latest Information Update: 22 May 2025
At a glance
- Drugs GSK-3858279 (Primary)
- Indications Pain
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
Most Recent Events
- 20 Jun 2023 Status changed from recruiting to completed.
- 27 Dec 2022 Planned End Date changed from 13 Jan 2023 to 30 Jun 2023.
- 27 Dec 2022 Planned primary completion date changed from 23 Sep 2022 to 9 Mar 2023.